EUVIMEDEUVIMED entdecken
Crossref

Avatrombopag for post‐transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single‐centre retrospective study

Cristian Alberdi-Lema iD, Beatriz García-Villaronga, Thais Linzodo-López iD, Esther Carcelero, Gisela Riu, Inés Monge-Escartín, María Suárez-Lledó, Laia Guardia, Alexandra Pedraza, Cristina Sanz iD, Paola Charry, Joan Cid und 7 weitere

British Journal of Haematology · 2026-03 · 208 (3) · 1027-1035

DOI: 10.1111/bjh.70378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 20.02.2026. Verfasst von Cristian Alberdi-Lema und 18 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Service, Division of Medicines, Hospital Clínic Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Thrombocytopenia, Hydrazines, Benzoates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic haematopoietic stem cell transplantation (allo‐HSCT) is potentially curative for high‐risk haematological diseases but may lead to persistent cytopenias such as poor graft function (PGF) or graft failure (GF). Thrombopoietin receptor agonists (TPO‐RAs) like eltrombopag or romiplostim are effective but have pharmacologic and practical limitations. This retrospective study evaluated avatrombopag, a novel oral TPO‐RA, in 11 adult patients with persistent thrombocytopenia following allo‐HSCT (8 with PGF and 3 with GF). Avatrombopag was initiated at 20 mg/day orally, escalated to 40 mg/day after a median of 21 days and up to 60 mg/day after a median of 36 days as the maximum dose in patients who did not achieve an adequate response. The median time to response was 55 days, with a median treatment duration of 134 days. A haematological response was achieved in all eight patients with PGF, with significant improvements in platelet counts and other haematopoietic lineages. In contrast, no response was documented in patients with GF. No severe adverse events or complications were reported. Notably, these findings suggest that avatrombopag is a promising alternative for PGF, offering practical advantages over other TPO‐RAs, although prospective studies are needed with a larger sample size of patients to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationThrombocytopeniaHydrazinesBenzoatesThiazolesHumansRetrospective StudiesAdultFemaleMaleMiddle AgedTransplantation, HomologousReceptors, ThrombopoietinAgedPlatelet CountYoung AdultTreatment OutcomeThiophenes

Stichwörter der Autor:innen

allogeneic haematopoietic stem cell transplantationavatrombopagpoor graft functionpost‐transplant thrombocytopeniathrombopoietin receptor agonists

Substanzen

avatrombopagReceptors, ThrombopoietinHydrazinesBenzoatesThiazolesThiophenes

Autor:innen und Institutionen

  • Pharmacy Service, Division of Medicines, Hospital Clínic Barcelona, Barcelona, Spain.
  • Hematopoietic Transplantation Unit and Hematology Department, Clinical Institute of Hematology and Oncology (ICAMS), Hospital Clínic Barcelona, Barcelona, Spain.
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Hematology Department, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
  • Blood and Tissue Bank, Hospital Clínic Barcelona, Barcelona, Spain.
  • Apheresis & Cellular Therapy Unit, Department of Hemotherapy and Hemostasis, ICAMS, Hospital Clínic Barcelona, Barcelona, Spain.

ORCID-Profile: Cristian Alberdi-Lema, Thais Linzodo-López, Cristina Sanz, Miquel Lozano, Carmen Martínez

Zitieren

APA

Alberdi-Lema, C., García-Villaronga, B., Linzodo-López, T., Carcelero, E., Riu, G., Monge-Escartín, I., Suárez-Lledó, M., Guardia, L., Pedraza, A., Sanz, C., Charry, P., Cid, J., Lozano, M., Carreras, E., Rosiñol, L., Martínez, C., Fernández-Avilés, F., Rovira, M., & Salas, M. Q. (2026). Avatrombopag for post‐transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single‐centre retrospective study. British Journal of Haematology, 208(3), 1027-1035. https://doi.org/10.1111/bjh.70378

Vancouver

Alberdi-Lema C, García-Villaronga B, Linzodo-López T, Carcelero E, Riu G, Monge-Escartín I, et al. Avatrombopag for post‐transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single‐centre retrospective study. British Journal of Haematology. 2026;208(3):1027-1035. doi:10.1111/bjh.70378

BibTeX
@article{AlberdiLema2026,
  author = {Alberdi-Lema, Cristian and García-Villaronga, Beatriz and Linzodo-López, Thais and Carcelero, Esther and Riu, Gisela and Monge-Escartín, Inés and Suárez-Lledó, María and Guardia, Laia and Pedraza, Alexandra and Sanz, Cristina and Charry, Paola and Cid, Joan and Lozano, Miquel and Carreras, Enric and Rosiñol, Laura and Martínez, Carmen and Fernández-Avilés, Francesc and Rovira, Montserrat and Salas, María-Queralt},
  title = {Avatrombopag for post‐transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single‐centre retrospective study},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {3},
  pages = {1027--1035},
  doi = {10.1111/bjh.70378}
}
Kostenlos starten →